SML3199

Monomethyl Auristatin E

≥98%

• Synonym(e): MMAE, MMAE toxin, Monomethylauristatin E, N-Methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide
• Empirische Formel (Hill-System): C₃₉H₆₇N₅O₇
• CAS-Nummer: 474645-27-7
• Molekulargewicht: 717.98
• UNSPSC-Code: 12352200

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98%
• Form: film or powder
• Farbe: white to off-white
• Lagertemp.: −20°C
• InChI: 1S/C39H67N5O7/c1-13-25(6)34(43(10)39(49)33(24(4)5)42-38(48)32(40-9)23(2)3)30(50-11)22-31(45)44-21-17-20-29(44)36(51-12)26(7)37(47)41-27(8)35(46)28-18-15-14-16-19-28/h14-16,18-19,23-27,29-30,32-36,40,46H,13,17,20-22H2,1-12H3,(H,41,47)(H,42,48)/t25-,26+,27+,29-,30+,32-,33-,34-,35+,36+/m0/s1
• InChIKey: DASWEROEPLKSEI-UIJRFTGLSA-N

Beschreibung

Biochem./physiol. Wirkung

Monomethyl Auristatin E (MMAE) is a highly potent peptidyl antimitotic agent that blocks the polymerization of tubulin. Monomethyl Auristatin E is a component of a clinically approved antibodydirected conjugates Brentuximab vedotin, Glembatumumab vedotin, Enfortumab vedotin and Polatuzumab vedotin.

Sicherheitshinweise

• Piktogramme: GHS06,GHS08
• Signalwort: Danger
• H-Sätze: H300 + H330,H340,H360FD,H370,H372,H412
• P-Sätze: P202 - P260 - P264 - P271 - P273 - P304 + P340 + P310
• Gefahreneinstufungen: Acute Tox. 1 Inhalation - Acute Tox. 1 Oral - Aquatic Chronic 3 - Muta. 1B - Repr. 1B - STOT RE 1 - STOT SE 1
• Zielorgane: male reproductive organs,Bone marrow,thymus,spleen,Liver
• Lagerklassenschlüssel: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable